Dr. Farago on Combination of Olaparib and Temozolomide in Small Cell Lung Cancer

Anna Farago, MD, PhD
Published: Monday, Apr 24, 2017



Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olaparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).

There is a phase I study investigating the combination of olaparib and temozolomide in patients with SCLC who have had progression after 1 prior line of platinum-based chemotherapy, explains Farago. This was designed as a 3 + 3 dose-escalation study, which escalated patients through 4 doses of the combination therapy.

The doses were found to be relatively tolerable, states Farago. The progression-free survival was 5.6 months with the median duration of treatment for patients being 5 months with some treated up to 1 year.
 


Anna Farago, MD, PhD, assistant, Medicine, Massachusetts General Hospital Cancer Center, and instructor, Medicine, at Harvard Medical School, discusses the combination of olaparib (Lynparza) and temozolomide (Temodar) for patients with small cell lung cancer (SCLC).

There is a phase I study investigating the combination of olaparib and temozolomide in patients with SCLC who have had progression after 1 prior line of platinum-based chemotherapy, explains Farago. This was designed as a 3 + 3 dose-escalation study, which escalated patients through 4 doses of the combination therapy.

The doses were found to be relatively tolerable, states Farago. The progression-free survival was 5.6 months with the median duration of treatment for patients being 5 months with some treated up to 1 year.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ALK-Positive NSCLC: Emerging Strategies to Inform Sequencing, Optimize Outcomes, and Address Unmet Clinical Needs Along the Disease ContinuumAug 29, 20181.5
Community Practice Connections™: Oncogenic Tumor Board in Advanced NSCLC: Leveraging Actionable Mutations Along the Disease Continuum to Optimize Patient OutcomesAug 30, 20182.0
Publication Bottom Border
Border Publication
x